Key market metrics for Dr Lal PathLabs (LALPATHLAB) listed on NSE. For healthcare sector companies, these metrics provide a snapshot of Dr Lal PathLabs's market valuation and enterprise value, essential for comparing against intrinsic value estimates.
We analyze Dr Lal PathLabs using multiple valuation models appropriate for HEALTHCARE companies. For HEALTHCARE companies, we use P/E Ratio Analysis, Discounted Cash Flow (DCF), and EPS Growth Valuation to determine fair value estimates for Dr Lal PathLabs stock.
10-year Price-to-Earnings ratio trend
Current P/E Ratio
53.75
Jun 03, 2026
5-Year Median P/E
63.14
5-Year Historical Median
Difference
-9.39
14.9%
Analysis: Dr Lal PathLabs's current P/E ratio is 14.9% below its 5-year median, suggesting the stock may be undervalued relative to its historical earnings performance.
The P/E ratio measures how much investors pay for each rupee of earnings (Share Price / EPS). A higher PE suggests the market expects strong future growth, while a lower PE may indicate undervaluation or slower growth prospects. Compare Dr Lal PathLabs's current PE against its historical median and HEALTHCARE peers to gauge whether the stock is trading at a premium or discount relative to its earnings.
Go beyond charts — get fair value estimates from multiple valuation models and detailed assessment breakdowns.
Just ₹833/month
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025